PJ34 HCl
Modify Date: 2024-01-03 13:29:41
PJ34 HCl structure
|
Common Name | PJ34 HCl | ||
|---|---|---|---|---|
| CAS Number | 344458-15-7 | Molecular Weight | 331.80 | |
| Density | N/A | Boiling Point | 539.1ºC at 760 mmHg | |
| Molecular Formula | C17H18ClN3O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 279.9ºC | |
Use of PJ34 HClPJ34 hydrochloride is an inhibitor of PARPl1/2 with IC50 of 110 nM and 86 nM, respectively. |
| Name | 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide,hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | PJ34 hydrochloride is an inhibitor of PARPl1/2 with IC50 of 110 nM and 86 nM, respectively. |
|---|---|
| Related Catalog | |
| Target |
PARP-2:86 nM (IC50) PARP-1:110 nM (IC50) PARP:110 nM (IC50) |
| In Vitro | PJ34 inhibits the PARP enzyme activity with an IC50 of 110±1.9 nM. To compare the neuroprotective properties of other PARP inhibitors in PC12 cells, PJ34 is evaluated using by LDH assay. PJ34 treatment also significantly and concentration dependently attenuates cell death at a concentration ranging from 10-7 to 10-5 M[1]. |
| In Vivo | To compare the potency and efficacy with other PARP inhibitors, PJ34 is evaluated at the doses of 3.2 and 10 mg/kg, respectively. PJ34 at the dose of 3.2 mg/kg significantly reduces cortical damage by 33%; however, 10 mg/kg dosing shows reversed effect (17% reduction)[1]. PJ34 (25 mg/kg) reduces the levels of TNF-α mRNA in ischemic animals by 70% and these values in treated mice do not differ from that of sham or naive animals. Treatment of ischemic mice with PJ34 reduces the level of E-selectin mRNA by 81% and that of ICAM-1 mRNA by 54%, compared to vehicle-treated ischemic mice[2]. |
| Kinase Assay | To assess the PARP-1 or PARP-2 inhibitory activity of FR247304, 3-AB, and PJ34, PARP activity is evaluated with minor modifications. PARP enzyme assay is carried out in a final volume of 100 μL consisting of 50 mM Tris-HCl (pH 8.0), 25 mM MgCl2, 1 mM dithiothreitol, 10 μg activated salmon sperm DNA, 0.1 μCi of [adenylate-32P]NAD, 0.2 units of recombinant human PARP for PARP-1 assay or 0.1 units of recombinant mouse PARP-2 for PARP-2 assay, and various concentrations of FR261529 or 3-AB. The reaction mixture is incubated at room temperature (23°C) for 15 min, and the reaction is terminated by adding 200 μL of ice-cold 20% trichloroacetic acid (TCA) and incubated at 4°C for 10 min. The precipitate is transferred onto GF/B filter and washed three times with 10% TCA solution and 70% ethanol. After the filter is dried, the radioactivity is determined by liquid scintillation counting. |
| Cell Assay | PC12 cell cultured are grown in Dulbecco's modified Eagle's medium supplemented with 5% (v/v) fetal calf serum, 5% (v/v) horse serum, and a 1% (v/v) penicillin-streptomycin antibiotics mixture. Cells are grown in an atmosphere of 95% air and 5% CO2 at 37°C. For all experiment, cells are seeded at a density of 4×104 cells/well in 96-well culture plates and allowed to attach overnight. For assessment of cell viability, hydrogen peroxide-induced cytotoxicity is quantified by a standard measurement of LDH release with the use of the LDH assay kit. Briefly, 6 h after hydrogen peroxide exposure, 20 μL of medium of each well is collected, and the solution prepared from LDH assay kit is added. After incubation at room temperature for 30 min, the reaction is stopped by addition of 1 N HCl, and absorbance is measured at 450 nm using a microplate reader. |
| Animal Admin | Rats[1] For transient focal ischemia, 9- to 10-week-old male Wistar rats (weighing 274-380 g) are used. FR247304, PJ34, or 3-AB, which is suspended with 0.5% methylcellulose, is administered at doses of 10 and 32 mg/kg for FR247304, 3.2 and 10 mg/kg for PJ34, or 32 and 100 mg/kg for 3-AB intraperitonially twice at 10 min before MCA occlusion and 10 min before recirculation. The administration volume is adjusted to 2 mL/kg. Mice[2] Male Swiss albino mice (27-32 g) are used. The PARP inhibitor, PJ34 (1.25, 12.5 or 25 mg/kg) is dissolved in isotonic saline (NaCl, 0.9%) and injected intraperitoneally, in a volume of 10 mL/kg, 15 min before ischemia and again 4 h after the onset of ischemia. Control ischemic mice and sham animals are given vehicle (saline). Naive animals are also included in the studies. |
| References |
| Boiling Point | 539.1ºC at 760 mmHg |
|---|---|
| Molecular Formula | C17H18ClN3O2 |
| Molecular Weight | 331.80 |
| Flash Point | 279.9ºC |
| PSA | 53.17000 |
| LogP | 3.11400 |
| Appearance of Characters | white to yellow |
| Storage condition | Desiccate at RT |
| Water Solubility | H2O: soluble22mg/mL |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Safety Phrases | 22-24/25 |
| RIDADR | NONH for all modes of transport |
| HS Code | 2933990090 |
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Ultraviolet radiation signaling through TLR4/MyD88 constrains DNA repair and plays a role in cutaneous immunosuppression.
J. Immunol. 194(7) , 3127-35, (2015) UV radiation (UVR) induces DNA damage, leading to the accumulation of mutations in epidermal keratinocytes and immunosuppression, which contribute to the development of nonmelanoma skin cancer. We rep... |
|
|
Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy.
Autophagy 11(2) , 214-24, (2015) Both apoptosis ("self-killing") and autophagy ("self-eating") are evolutionarily conserved processes, and their crosstalk influences anticancer drug sensitivity and cell death. However, the underlying... |
|
|
Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation.
Nat. Med. 7 , 108, (2001) Diabetic patients frequently suffer from retinopathy, nephropathy, neuropathy and accelerated atherosclerosis. The loss of endothelial function precedes these vascular alterations. Here we report that... |
| 2-Phenanthridineacetamide, 5,6-dihydro-N,N-dimethyl-6-oxo-, hydrochloride (1:1) |
| 2-(Dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide hydrochloride |
| PARP Inhibitor VIII,PJ34 |
| s7300 |
| PJ-34 hydrochloride hydrate |
| PJ 34 Hydrochloride |
| N,N-Dimethyl-2-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide hydrochloride (1:1) |
| Acetamide (N-(5,6-dihydro-6-oxo-2-phenanthridinyl)-2-(dimethylamino) |
| N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-dimethylamino)acetamide hydrochloride |
| N,N-Dimethyl-2-(6-oxo-5,6-dihydro-2-phenanthridinyl)acetamide hydrochloride (1:1) |
| PJ34 HCl |
| PJ34 (hydrochloride) |